Results 51 to 60 of about 41,669 (215)

The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis

open access: yesAdvanced Science, EarlyView.
This review summarizes recent advances in understanding the immune microenvironment's role in fibrosis, focusing on phenotypic/functional alterations of immune cells and their dynamic interactions with other cellular constituents within tissues. The authors further explore therapeutic opportunities and challenges in targeting immune microenvironment ...
Xiangqi Chen   +6 more
wiley   +1 more source

Capillaroscopy in 2016 : new perspectives in systemic sclerosis [PDF]

open access: yes, 2016
Systemic sclerosis (SSc) is an autoimmune disorder of unknown etiology characterized by early impairment of the microvascular system. Nailfold microangiopathy and decreased peripheral blood perfusion are typical clinical aspects of SSc.
Cutolo, M   +6 more
core   +1 more source

Elevated expression of type VII collagen in the skin of patients with systemic sclerosis. Regulation by transforming growth factor-beta. [PDF]

open access: yes, 1994
A hallmark of systemic sclerosis (SSc) is the development of tissue fibrosis. Excessive production of several connective tissue components normally present in the dermis, including type I, III, V, and VI collagens as well as fibronectin and proteoglycans,
Christiano, Angela M.   +5 more
core   +3 more sources

Uncommon skeletal findings in systemic sclerosis (scleroderma)

open access: yesSouth African Journal of Radiology, 2002
Scleroderma or progressive systemic sclerosis is a diffuse disease characterised by excessive deposition of collagen and small-vessel arteritis. Systemic sclerosis is divided into two groups. 1.
Betsie van der Walt   +2 more
doaj   +1 more source

Hand Swelling and Other Non–Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts

open access: yesArthritis &Rheumatology, EarlyView.
Objective Raynaud phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc ...
Iqtidar Hanif   +32 more
wiley   +1 more source

Nintedanib for systemic sclerosis–associated interstitial lung disease [PDF]

open access: yes, 2019
BackgroundInterstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects ...
Alves, Margarida   +16 more
core   +3 more sources

Formyl Peptide Receptor 2 Activation Ameliorates Dermal Fibrosis and Inflammation in Bleomycin-Induced Scleroderma

open access: yesFrontiers in Immunology, 2019
Systemic sclerosis is a profibrotic autoimmune disease mediated by the dysregulation of extracellular matrix synthesis. Formyl peptide receptor 2 (Fpr2) is a G protein-coupled receptor that modulates inflammation and host defense by regulating the ...
Gyu Tae Park   +7 more
doaj   +1 more source

Fat Grafting Subjectively Improves Facial Skin Elasticity and Hand Function of Scleroderma Patients

open access: yesPlastic and Reconstructive Surgery, Global Open, 2021
Summary:. Systemic scleroderma is a chronic connective tissue disease characterized by internal organ and skin fibrosis. Unfortunately, there is a lack of efficacious treatments for cutaneous manifestations, and alternative interventions should be ...
Amy L. Strong, MD, PhD   +3 more
doaj   +1 more source

Mucosal‐Associated Invariant T Cells in Rheumatic Diseases

open access: yesArthritis &Rheumatology, EarlyView.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek   +7 more
wiley   +1 more source

Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? [PDF]

open access: yes, 2006
It has been postulated that endothelial cell injury is the initiating event in the pathogenesis of systemic sclerosis, causing attraction, attachment, migration and infiltration of activated T-cells and subsequent production of cytokines and growth ...
Derk, Chris T., Jimenez, Sergio A.
core   +2 more sources

Home - About - Disclaimer - Privacy